Close Navigation
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
Overlay

Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia

17th March 2021

Useful Tools

Download, print or share this article

Print Print Article Email Email Article
Print Save Article
Share Article
TwitterTwitterLinkedInLinkedInFacebookFacebook